Skip to content
⌘KStart free
AI InfrastructureDefenseQuantumAll studies →

GEMINI-NSCLC: NSCLC Biomarker Study

← catalyst calendar

NCT05236114 · readout ≤ 1,046 d

Sponsored by Tempus AI (industry) · TEM — their whole pipeline →. With AstraZeneca.

Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,200estimated
Sites
58
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-06-22actualWhen the study began enrolling
Primary completionJun 2029estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionJun 2029estimatedThe whole study's end, after follow-up
First posted2022-02-11actualWhen this record first appeared on the registry
Results posted—When the sponsor posted results to the registry
Record updated2026-02-05actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Non-Small Cell Lung Cancer

Intervention

  • Other: Observation

Primary outcomes

what the primary-completion date above is the date OF
Real-World Disease Free Survival (rwDFS)
measured 5 years
Real-World Overall Survival (rwOS)
measured 3 years

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · TEM's whole pipeline · Catalyst calendar · Every registered study · What changed

Related →Calendar (CAL)Screener (SCR)Watchlist (WL)